193 related articles for article (PubMed ID: 35899444)
21. Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations.
Jiang ZB; Huang J; Xie C; Li X; Liu L; He J; Pan H; Huang L; Fan XX; Yao XJ; Xie Y; Li N; Liu L; He JX; Leung EL
Oncol Rep; 2016 Jul; 36(1):365-75. PubMed ID: 27121230
[TBL] [Abstract][Full Text] [Related]
22. Does lung cancer mutation status and targeted therapy predict for outcomes and local control in the setting of brain metastases treated with radiation?
Wang TJ; Saad S; Qureshi YH; Jani A; Nanda T; Yaeh AM; Rozenblat T; Sisti MB; Bruce JN; McKhann GM; Lesser J; Halmos B; Stoopler MB; Lassman AB; Cheng SK; Isaacson SR
Neuro Oncol; 2015 Jul; 17(7):1022-8. PubMed ID: 25910841
[TBL] [Abstract][Full Text] [Related]
23. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
[TBL] [Abstract][Full Text] [Related]
24. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.
Doebele RC; Pilling AB; Aisner DL; Kutateladze TG; Le AT; Weickhardt AJ; Kondo KL; Linderman DJ; Heasley LE; Franklin WA; Varella-Garcia M; Camidge DR
Clin Cancer Res; 2012 Mar; 18(5):1472-82. PubMed ID: 22235099
[TBL] [Abstract][Full Text] [Related]
25. Kirsten rat sarcoma inhibitors in clinical development against nonsmall cell lung cancer.
Li Y; Hu L; Xu C
Curr Opin Oncol; 2022 Jan; 34(1):66-76. PubMed ID: 34690284
[TBL] [Abstract][Full Text] [Related]
26. A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer.
Park J; Cho YH; Shin WJ; Lee SK; Lee J; Kim T; Cha PH; Yang JS; Cho J; Min DS; Han G; Lee HY; Choi KY
Sci Rep; 2019 Jan; 9(1):648. PubMed ID: 30679620
[TBL] [Abstract][Full Text] [Related]
27. Detection of an EML4-ALK fusion mutation secondary to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer: a case report.
Ren KH; Qin WW; Wang Y; Peng JC; Hu WX
Ann Palliat Med; 2022 Jul; 11(7):2503-2509. PubMed ID: 35927783
[TBL] [Abstract][Full Text] [Related]
28. [Clinical Analysis of 107 NSCLC Patients Harboring KRAS Mutation].
Zhang Q; Wang J; Li X; Zhang H; Nong J; Qin N; Zhang X; Wu Y; Yang X; Lv J; Zhang S
Zhongguo Fei Ai Za Zhi; 2016 May; 19(5):257-62. PubMed ID: 27215453
[TBL] [Abstract][Full Text] [Related]
29. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
Zhang K; Yuan Q
J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
[TBL] [Abstract][Full Text] [Related]
30. Targeting Epidermal Growth Factor Receptor in Non-Small-Cell-Lung Cancer: Current State and Future Perspective.
Bao SM; Hu QH; Yang WT; Wang Y; Tong YP; Bao WD
Anticancer Agents Med Chem; 2019; 19(8):984-991. PubMed ID: 30868964
[TBL] [Abstract][Full Text] [Related]
31. Rare Complex Mutational Profile in an ALK Inhibitor-resistant Non-small Cell Lung Cancer.
Azzato EM; Deshpande C; Aikawa V; Aggarwal C; Alley E; Jacobs B; Morrissette J; Daber R
Anticancer Res; 2015 May; 35(5):3007-12. PubMed ID: 25964588
[TBL] [Abstract][Full Text] [Related]
32. [Research Progress of KRAS Mutation in Non-small Cell Lung Cancer].
Liu L; Wei S
Zhongguo Fei Ai Za Zhi; 2018 May; 21(5):419-424. PubMed ID: 29764594
[TBL] [Abstract][Full Text] [Related]
33. Concomitance of P-gp/LRP Expression with EGFR Mutations in Exons 19 and 21 in Non-Small Cell Lung Cancers.
Wei H; Lu W; Li M; Zhang Q; Lu S
Yonsei Med J; 2016 Jan; 57(1):50-7. PubMed ID: 26632382
[TBL] [Abstract][Full Text] [Related]
34. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
[TBL] [Abstract][Full Text] [Related]
35. Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK).
Kong X; Pan P; Sun H; Xia H; Wang X; Li Y; Hou T
J Med Chem; 2019 Dec; 62(24):10927-10954. PubMed ID: 31419130
[TBL] [Abstract][Full Text] [Related]
36. KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies.
Pan W; Yang Y; Zhu H; Zhang Y; Zhou R; Sun X
Oncotarget; 2016 Feb; 7(7):8373-88. PubMed ID: 26840022
[TBL] [Abstract][Full Text] [Related]
37. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies.
Mao C; Qiu LX; Liao RY; Du FB; Ding H; Yang WC; Li J; Chen Q
Lung Cancer; 2010 Sep; 69(3):272-8. PubMed ID: 20022659
[TBL] [Abstract][Full Text] [Related]
38. Anaplastic Lymphoma Kinase Testing: IHC vs. FISH vs. NGS.
Niu X; Chuang JC; Berry GJ; Wakelee HA
Curr Treat Options Oncol; 2017 Nov; 18(12):71. PubMed ID: 29143897
[TBL] [Abstract][Full Text] [Related]
39. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
[TBL] [Abstract][Full Text] [Related]
40. ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.
Alì G; Proietti A; Pelliccioni S; Niccoli C; Lupi C; Sensi E; Giannini R; Borrelli N; Menghi M; Chella A; Ribechini A; Cappuzzo F; Melfi F; Lucchi M; Mussi A; Fontanini G
Arch Pathol Lab Med; 2014 Nov; 138(11):1449-58. PubMed ID: 24885803
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
